One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

Aim Assess long‐term safety and efficacy of the dipeptidlyl peptidase-4 (DPP‐4) inhibitor vildagliptin in 369 patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment (RI). Methods Double‐blind, randomized, parallel‐group, 52‐week clinical trial comparing safety and effi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2012-11, Vol.14 (11), p.1032-1039
Hauptverfasser:	Kothny, W., Shao, Q., Groop, P.-H., Lukashevich, V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adamantane - administration & dosage Adamantane - analogs & derivatives Adamantane - pharmacology adverse drug reactions Adverse events Aged antidiabetic drug Antidiabetics Clinical trials Comorbidity Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Diabetic Nephropathies - blood Diabetic Nephropathies - drug therapy Diabetic Nephropathies - physiopathology Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - pharmacology Double-Blind Method DPP-IV inhibitor Drug Administration Schedule Female Glomerular Filtration Rate GLP-1 Humans Kidney Failure, Chronic - blood Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - physiopathology Male Nitriles - administration & dosage Nitriles - pharmacology Patients Placebos Population studies Pyrrolidines - administration & dosage Pyrrolidines - pharmacology Safety Treatment Outcome type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aim Assess long‐term safety and efficacy of the dipeptidlyl peptidase-4 (DPP‐4) inhibitor vildagliptin in 369 patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment (RI). Methods Double‐blind, randomized, parallel‐group, 52‐week clinical trial comparing safety and efficacy of vildagliptin (50 mg qd, n = 216) and placebo (n = 153) added to ongoing stable antihyperglycaemic treatment, in patients with T2DM and moderate or severe (glomerular filtration rate [GFR] ≥30 to
ISSN:	1462-8902 1463-1326
DOI:	10.1111/j.1463-1326.2012.01634.x